Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Targeted Therapy Treatment Innovations in AML : Episode 4
Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
EP: 1.Role of First Generation FLT3 Inhibitors in AML
EP: 2.Role of Second Generation FLT3 Inhibitors in AML
EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Now Viewing
EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP: 5.Role of Venetoclax in Treatment of AML
EP: 6.Part 1: Practical Considerations For Venetoclax in AML
EP: 7.Part 2: Practical Considerations For Venetoclax in AML
EP: 8.5-Year Follow-Up Data For CPX-351 in AML
EP: 9.CPX-351 in Clinical Practice For AML
Related Videos
Related Content
